Senseonics Holdings, Inc. · NASDAQ:SENS
Senseonics — Investor Presentation (November 2025)
19 slides from Senseonics's investor presentation, November 2025
Slide 1: Investor presentation November 2025
Investor presentation November 2025
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Senseonics Holdings, Inc. (the “Company,” “Senseonics,” “we,” “us”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Any statements in t
Slide 3: One Year. One CGM. One Company.
One Year. One CGM. One Company. Disruptive One Focused Commercial Clear potential Company. strategy momentum roadmap Unlocking potential. Accelerating growth. 3
Slide 4: Investment highlights
Investment highlights ✓ $13.5bn global market size in 2025* Disruptive Potential Addressing key patient pain points in a large, growing and underpenetrated CGM market ✓ #1 longevity and #1 survivability ✓ A new level of control and agility Fully Integrated Capabilities Unlocking operational efficien
Slide 5: The CGM market is primed for growth and disruption
The CGM market is primed for growth and disruption Large and growing market currently dominated by similar products with significant drawbacks $13.5bn Common CGM 2025 global CGM market* Frustrations (~20% CAGR to 2030) The market remains significantly Sensor lifetime underpenetrated 38% Early failur
Slide 6: One Year. One CGM. Gaining momentum
One Year. One CGM. Gaining momentum… 160% Longest Lasting CGM new patient growth in Q3 2025 The world’s first the U.S. over the prior year and only One …by delivering value Year CGM Industry-Leading Survivability system. Empowering patients with more Exceptional Accuracy autonomy, flexibility, and c
Slide 7: One Company.
One Company. Unlocking potential and accelerating growth as a fully-integrated commercial organization. Key benefits: Key principles of the integration: Unlocking operational efficiencies 1. Maintain Momentum Simplifying workflow and communication, freeing resource to drive strategy Accelerating our
Slide 8: Focused on Robust Growth
Focused on Robust Growth High conviction in our ability to deliver results through executing a focused commercial strategy. Strategic priorities Key growth drivers Awareness Generate demand by driving patient (DTC) and HCP leads Access Grow inserter network and expand coverage Market Expand reach, c
Slide 9: Growth Initiatives and Investments
Growth Initiatives and Investments We are focused on executing our strategy to unlock the potential of Eversense 365. Awareness Access Penetration Retention DTC marketing Expand and optimize inserter Expand commercial team and Evolve onboarding process network (inc. EON Care strategy) capacity HCP m
Slide 10: EON Care: Expanding Access
EON Care : Expanding Access A purpose-built subsidiary delivering mobile insertions to improve patient access nationwide Extends reach Enables Boosts Centralized Reimbursable to untapped prescriber-only field-sales scheduling & and self- patients physicians* efficiency patient training funding Our p
Slide 11: Early Execution and Momentum
Early Execution and Momentum Our commercial strategy is delivering results in 2025; a solid foundation to accelerate growth. New Patient Growth Inserter Growth Prescriber Growth Covered Lives >1000 new prescribers 300m covered lives 2024 2025 2024 2025 2024 2025 Covered Non-covered HCP DTC External
Slide 12: Addressing Patient Unmet Needs
Addressing Patient Unmet Needs Insights from patients and practitioners showcase product differentiation and real-life benefits. 90% of new patients now coming fromI’llcompetitors never go back to other CGMs Fits into 10% are new to CGM Best move Imyrecommended it to my lifestyle HCP, now she's a pr
Slide 13: Building a Sustainable Financial Profile
Building a Sustainable Financial Profile Well-positioned to reach our target of long-term profitability. 2026: Planned enhancements Goal: Future state as a following resumption of fully-integrated business commercialization of Eversense • Sustainable earnings growth Where we are today1 • 70%+ gross
Slide 14: Product Vision
Product Vision Uniquely differentiated long-term technology solution with multiple product configurations with AID and Smart Pen integration Sensor. All patient segments. No sensor changes for 1 year. No transmitter. No daily calibration. Product development timelines, regulatory clearance and speci
Slide 15: GEMINI. FREEDOM.
GEMINI. FREEDOM. The first CGM with optional The first completely on-body transmitter invisible CGM Integrated 1-year battery Integrated 1-year battery; no transmitter Real-time CGM w/ transmitter; Direct Bluetooth communication FGM* w/o transmitter between sensor and handheld For insulin and food d
Slide 16: The Journey Ahead
The Journey Ahead We have growth levers to pull and catalysts ahead. We are now in control of our own destiny. One Year. One CGM. One Gemini – Launch Freedom – Launch Company. No transmitter – direct European Market One-year sensor w/ battery US commercial integration One Year. One CGM. One complete
Slide 17: Shaping the Future of Diabetes
Shaping the Future of Diabetes Continuing to push the boundaries in CGM. Innovating to improve the patient experience. 10 Years Ago Today Tomorrow Short-term CGM Long-term CGM Invisible CGM Traditional CGMs were an Eversense 365 is the The future is no on-body important step from BGM cutting edge of
Slide 18: Experienced Management Team
Experienced Management Team Timothy Goodnow Brian Hansen Francine R. Kaufman Rick Sullivan Mukul Jain President & Chief Chief Commercial Chief Medical Officer Chief Financial Officer Chief Operating Officer Executive Officer Officer* *As of January 1, 2026 18
Slide 19: Thank you
One Year. One CGM. One Company. Unlocking potential. Accelerating growth. Thank you 19
Senseonics Holdings — Investor Presentation (November 2025) on 6ix